FDA approves Bristol Myers Squibb's ZENBEXUS, first CELMoD therapy for multiple myeloma
Hematogenix said its multiple myeloma minimal residual disease assay measured the primary efficacy endpoint supporting FDA accelerated approval of Bristol Myers Squibb's ZENBEXUS, making the test part of the regulatory foundation for the first approved CELMoD therapy in multiple myeloma.
PR NEWSWIRE / FILEThe story
Hematogenix said its proprietary MM MRD assay was used to measure the primary efficacy endpoint cited in the FDA’s accelerated approval of ZENBEXUS, also known as iberdomide. The announcement was issued from Tinley Park, Illinois, on August 19, 2026, and describes ZENBEXUS as the first approved CELMoD therapy for multiple myeloma.
The direct corporate read-through is to Bristol Myers Squibb, whose drug received the regulatory decision, while Hematogenix is presented as the specialized trial-services and biomarker company supporting the registration. No approval sales forecast, label detail beyond the accelerated-approval designation, or commercial terms between the companies were provided.
The next datapoints are the confirmatory evidence required for the accelerated approval, the timing and scale of the ZENBEXUS launch, and any disclosures from BMY on pricing, uptake, or portfolio impact. The supplied financial snapshot shows BMY with FY2025 revenue of $48.2B, down 0.2% year over year, a 14.6% net margin, and $3.46 diluted EPS, but it does not isolate this therapy’s contribution.
Our read · Wed, Aug 19
Hematogenix’s assay measured the primary endpoint supporting FDA accelerated approval of Bristol Myers Squibb’s ZENBEXUS (BMY).
Why. The regulatory milestone expands BMY’s marketed oncology portfolio and creates a concrete commercial catalyst, but the supplied figures provide no ZENBEXUS sales estimate or valuation gap to support a larger move. BMY’s $48.2B FY2025 revenue base and 14.6% net margin make the approval strategically positive while leaving the near-term P&L effect modest until uptake is disclosed.
Both cases
What could change this view: The trade fails if launch demand is weak or confirmatory evidence does not support continued approval, leaving the announcement with little measurable earnings impact.
Who reported it · 1
Keep reading
Latest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeBeijing plans to bar young red-chip firms from overseas listingsGerman producer prices jump 8.1% in October as industrial inflation acceleratesContinue on the Wire →Top this week
Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayAbout this report
Reported by PR Newswire as Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
, . Who answers for this
The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →